Postoperative effect of sufentanil preemptive analgesia combined with psychological intervention on breast cancer patients

Abstract

Objectives To explore the postoperative effects of sufentanil preemptive analgesia combined with psychological intervention on breast cancer patients undergoing radical surgery. Methods 112 female breast cancer patients aged 18–80 years old who underwent radical surgery by the same surgeon were randomly divided into 4 groups, and there were 28 patients in each group. Patients in group A were given 10 µg sufentanil preemptive analgesia combined with perioperative psychological support therapy (PPST), group B had only 10 µg sufentanil preemptive analgesia, group C had only PPST, and group D were under general anesthesia with conventional intubation. Visual analogue scoring (VAS) was used for analgesic evaluation at 2, 12 and 24 h after surgery and compared among the four groups by ANOVA method. Results The awakening time of patients in group A or B was significantly shorter than that in group C or D, and the awakening time in group C was significantly shorter than that in group D. Moreover, patients in group A had the shortest extubation time, while the group D had the longest extubation time. The VAS scores at different time points showed significant difference, and the VAS scores at 12 and 24 h were significantly lower than those at 2 h (P < 0.05). The VAS scores and the changing trend of VAS scores were varied among the four groups (P < 0.05). In addition, we also found that patients in group A had the longest time to use the first pain medication after surgery, while patients in group D had the shortest time. But the adverse reactions among the four groups showed no difference. Conclusions Sufentanil preemptive analgesia combined with psychological intervention can effectively relieve the postoperative pain of breast cancer patients.

Effects of Sufentanil on proliferation, migration and epithelial-mesenchymal transition of endometrial cancer

“…Sufentanil finds its applicability in diverse pain management scenarios, serving as an effective choice for postoperative analgesia, particularly following surgical and gynecological procedures, and is indispensable in the fields of anesthesia and pain management [8]. Its principal mechanism of action involves targeting opioid µ receptors, making it frequently used as an opioid analgesic [9]. It has been reported that the analgesic potency of Sufentanil surpasses that of fentanyl by a magnitude of 5-10 times [9] and that Sufentanil, as a fatsoluble substance, has high binding rates to plasma protein [9].…”

“…Its principal mechanism of action involves targeting opioid µ receptors, making it frequently used as an opioid analgesic [9]. It has been reported that the analgesic potency of Sufentanil surpasses that of fentanyl by a magnitude of 5-10 times [9] and that Sufentanil, as a fatsoluble substance, has high binding rates to plasma protein [9]. In addition, research has shown that Sufentanil preconditioning exerts a protective effect on brain-related diseases [10], as well as antitumor effects [9,11].…”

“…It has been reported that the analgesic potency of Sufentanil surpasses that of fentanyl by a magnitude of 5-10 times [9] and that Sufentanil, as a fatsoluble substance, has high binding rates to plasma protein [9]. In addition, research has shown that Sufentanil preconditioning exerts a protective effect on brain-related diseases [10], as well as antitumor effects [9,11]. Notably, Sufentanil has been shown to inhibit gastric cancer cell proliferation and induce apoptosis [12], affect the proliferation and epithelialmesenchymal transition (EMT) of lung cancer cells through modulation of the Wnt/β-catenin axis [13], inhibit the proliferation and metastasis of esophageal cancer by suppressing NF-κB and Snail pathways [14], and inhibits the proliferation and promotes apoptosis of cervical cancer cells by regulating the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis [15] at concentrations ranging between 1 nM-20 nM [11][12][13][14][15].…”